bluebird bio, Inc. (NASDAQ:BLUE) CEO Andrew Obenshain Sells 21,805 Shares
bluebird bio, Inc. (NASDAQ:BLUE) CEO Andrew Obenshain Sells 21,805 Shares
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) CEO Andrew Obenshain sold 21,805 shares of the business's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now directly owns 247,131 shares in the company, valued at $1,084,905.09. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
蓝鸟生物公司(Bluebird Bio,Inc.)首席执行官安德鲁·奥本斯坦在一笔日期为8月4日(星期四)的交易中出售了21,805股蓝鸟生物股票。这些股票的平均价格为4.39美元,总价值为95,723.95美元。交易完成后,首席执行官现在直接拥有公司247,131股,价值1,084,905.09美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以在美国证券交易委员会的网站上看到。
bluebird bio Stock Performance
蓝鸟生物股票表现
NASDAQ:BLUE traded up $0.75 on Monday, hitting $6.34. The stock had a trading volume of 10,617,046 shares, compared to its average volume of 4,637,974. bluebird bio, Inc. has a 1 year low of $2.87 and a 1 year high of $25.39. The firm's fifty day simple moving average is $4.22 and its two-hundred day simple moving average is $4.76. The stock has a market cap of $453.02 million, a P/E ratio of -0.74 and a beta of 1.29.
纳斯达克:蓝色周一上涨0.75美元,触及6.34美元。该股成交量为10,617,046股,而其平均成交量为4,637,974股。蓝鸟生物公司的一年低点为2.87美元,一年高位为25.39美元。该公司的50日简单移动均线切入位为4.22美元,200日简单移动均线切入位为4.76美元。该股市值为4.5302亿美元,市盈率为-0.74,贝塔系数为1.29。
bluebird bio (NASDAQ:BLUE – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.40). The firm had revenue of $1.95 million for the quarter, compared to the consensus estimate of $0.17 million. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. bluebird bio's revenue for the quarter was up 117.6% on a year-over-year basis. During the same period last year, the company posted ($3.07) earnings per share. Equities research analysts predict that bluebird bio, Inc. will post -5.07 EPS for the current year.
青鸟生物(纳斯达克:Blue-Get Rating)上一次公布季度收益数据是在5月9日星期一。这家生物技术公司公布了本季度每股收益(1.66美元),低于普遍预期的(1.26美元)和(0.40美元)。该公司本季度营收为195万美元,而市场普遍预期为17万美元。蓝鸟生物的净利润率为负2,141.34%,净资产回报率为负130.19%。蓝鸟生物本季度的营收同比增长了117.6。去年同期,该公司公布的每股收益为3.07美元。股票研究分析师预测,蓝鸟生物公司本年度每股收益将达到5.07美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Institutional Investors Weigh In On bluebird bio
机构投资者参与蓝鸟生物
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLUE. Keybank National Association OH purchased a new position in shares of bluebird bio in the second quarter worth about $42,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in bluebird bio by 81.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 94,875 shares of the biotechnology company's stock valued at $393,000 after acquiring an additional 42,503 shares during the period. Monaco Asset Management SAM bought a new position in shares of bluebird bio in the second quarter worth $1,267,000. SG Americas Securities LLC grew its position in shares of bluebird bio by 133.1% in the second quarter. SG Americas Securities LLC now owns 28,253 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 16,130 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of bluebird bio by 45.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 313,207 shares of the biotechnology company's stock valued at $1,297,000 after purchasing an additional 97,827 shares during the period. 96.38% of the stock is currently owned by institutional investors.
一些对冲基金和其他机构投资者最近增持或减持了Blue的股份。KeyBank National Association OH在第二季度购买了蓝鸟生物的新头寸,价值约42,000美元。康纳-克拉克-伦恩投资管理有限公司在第二季度增持了81.2%的蓝鸟生物股份。康纳·克拉克和伦恩投资管理有限公司目前持有这家生物技术公司94,875股股票,价值39.3万美元,在此期间又购买了42,503股。摩纳哥资产管理公司SAM在第二季度购买了蓝鸟生物的新头寸,价值1,267,000美元。第二季度,SG America Securities LLC持有的蓝鸟生物股票头寸增加了133.1%。SG America Securities LLC现在拥有28,253股这家生物技术公司的股票,价值11.7万美元,上个季度又购买了16,130股。最后,未来资产全球投资有限公司在第二季度增持了蓝鸟生物45.4%的股份。未来资产全球投资有限公司现在拥有313,207股这家生物技术公司的股票,价值1,297,000美元,在此期间又购买了97,827股。96.38%的股票目前由机构投资者持有。
About bluebird bio
关于蓝鸟传记
(Get Rating)
(获取评级)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
蓝鸟生物公司是一家生物技术公司,研究、开发和商业化针对严重遗传病的变革性基因疗法。其用于治疗严重遗传性疾病的候选产品包括用于治疗输血依赖型β-地中海贫血的贝替贝吉基因Autotemcel;用于治疗镰状细胞病(SCD)的lovotieglogene autemcel;以及用于治疗大脑肾上腺脑白质营养不良的伊利伐多烯Autotemcel。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- How to Use the MarketBeat Dividend Calculator
- Two Appealing Biotech Stocks for Two Distinct investors
- Is Tyson Foods A Buy On Post-Earnings Weakness?
- Is DoorDash Ready To Sprint Higher?
- Electric Vehicles Can Drive Alcoa Stock Higher
- 免费获取StockNews.com关于蓝鸟生物的研究报告(蓝色)
- 如何使用MarketBeat分红计算器
- 两只对两个不同投资者有吸引力的生物技术股票
- 泰森食品是在盈利疲软的基础上买入的吗?
- DoorDash准备好冲刺更高了吗?
- 电动汽车可以推动美国铝业股价走高
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
获得蓝鸟生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对蓝鸟生物和相关公司的最新新闻和分析师评级的每日简明摘要。